INTRACAMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS
First Claim
Patent Images
1. A method for treating an ocular condition comprising the steps of:
- providing at least two biodegradable sustained release implants containing at least one therapeutic agent;
implanting the at least two biodegradable sustained release implants into the anterior chamber of an eye; and
treating the ocular condition,wherein the at least two biodegradable sustained release implants release about 100 ng per day of the at least one bioactive agent for a period greater than about 1 month.
2 Assignments
0 Petitions
Accused Products
Abstract
Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
77 Citations
20 Claims
-
1. A method for treating an ocular condition comprising the steps of:
-
providing at least two biodegradable sustained release implants containing at least one therapeutic agent; implanting the at least two biodegradable sustained release implants into the anterior chamber of an eye; and treating the ocular condition, wherein the at least two biodegradable sustained release implants release about 100 ng per day of the at least one bioactive agent for a period greater than about 1 month. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method for treating glaucoma in an eye comprising the steps of:
-
providing at least two biodegradable sustained release implants containing at least one therapeutic agent; implanting the at least two biodegradable sustained release implants into the anterior chamber of the eye; allowing a sufficient time for the at least two biodegradable sustained release implants to settled out in the inferior angle; allowing a sufficient time for the at least two biodegradable sustained release implants to release the at least one therapeutic agent; and treating glaucoma, wherein the at least two biodegradable sustained release implants release about 100 ng per day of the at least one bioactive agent for a period greater than about 1 month. - View Dependent Claims (16, 17, 18, 19, 20)
-
Specification